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Abstract 23 
Aims: To examine the associations between diastolic dysfunction indices and long-term risk of all-24 
cause mortality in adults over 23 year follow-up.  25 
Methods and results: Participants (n=2734) of the population-based Tromsø Study of Norway had 26 
echocardiography in 1994-1995. Of these 67% were repeated in 2001 and/or 2007-2008. Mortality 27 
between 1994 and 2016 was determined by linkage to the national death registry. Cox regression was 28 
used to model the hazard of all-cause mortality in relation to left atrial parameters (treated as time-29 
dependent using repeated measurements) adjusted for traditional risk factors and cardiovascular 30 
disease. 31 
During the follow-up 1399 participants died. Indexed left atrial diameter, mitral peak E deceleration 32 
time and mitral peak E to peak A ratio showed an U-shaped association with all-cause mortality. 33 
Combining left atrial diameter with mitral peak E deceleration time increased the prognostic accuracy 34 
for all-cause mortality whereas adding mitral peak E to peak A ratio did not increase prognostic value. 35 
We estimated new optimal cut-off values of left atrial diameter, mitral peak E deceleration time and 36 
mitral peak E to peak A ratio for all-cause mortality outcome. E/e’ had a cubic relation to mortality.            37 
Conclusion: Both enlarged and small left atrial diameter were associated with increased all-cause 38 
mortality risk. A combination of Doppler-based left ventricle filling parameters had an incremental 39 
effect on all-cause mortality risk. The cut-off values of diastolic dysfunction indices we determined 40 
had similar all-cause mortality prediction ability as those recommended by American Association of 41 
Echocardiography and European Association of Cardiovascular Imaging. 42 
 43 
Key words: Left atrial diameter, prognosis, all-cause mortality, diastolic dysfunction, epidemiology, 44 
echocardiography. 45 
  46 
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Introduction 47 
Heart failure (HF) is associated with reduced quality of life and premature mortality (1). It is defined 48 
as a clinical syndrome associated with a wide range of left ventricular (LV) structural and functional 49 
abnormalities of different underlying aetiologies (2). Recent data suggest that the incidence of HF with 50 
reduced LV ejection fraction (HFrEF) and HF with mid-range LV ejection fraction (HFmrEF) is 51 
decreasing while incidence of HF with preserved LV ejection fraction (HFpEF) is increasing (1).  52 
Detection of asymptomatic diastolic dysfunction is a strong risk factor for developing HFpEF (3). Left 53 
atrial (LA) diameter measured in M-mode and mitral flow measurements such as the ratio of the 54 
maximal E wave to the maximal A wave (E/A ratio) and the deceleration time of the E wave (DT) has 55 
been commonly used as indices of diastolic dysfunction. Enlarged LA diameter is a significant 56 
predictor of adverse cardiovascular events (4). Additionally, LA enlargement has been found to be an 57 
independent predictor of HF development, atrial fibrillation, coronary heart disease, stroke and all-58 
cause mortality (5-8).  59 
A short as well as long DT are associated with poor cardiovascular outcomes (9). E/A ratio is used for 60 
evaluating filling pressure and degree of diastolic dysfunction and also provides prognostic 61 
information (10). 62 
The number of studies on the diagnostic impact of LA size and function through the last decades 63 
indicates its importance for cardiovascular health (11). However, there is a lack of data on associations 64 
between lower ranges of LA size and all-cause mortality rates. The American Society of 65 
Echocardiography (ASE) and European Association of Cardiovascular Imaging (EACVI) has put 66 
forward a series of LA diameter cut-offs that are defined purely in terms of percentiles of the 67 
distribution. Their ability to predict mortality has not so far been ascertained (12).  68 
The recent ASE and EACVI guidelines define diastolic dysfunction in terms of a combination of 69 
statistically “normal” values of mitral flow indices derived from a small sample of healthy individuals 70 
and predictions of mortality by LA diameter from a surveys of the general population (13). These 71 
guidelines have not validated the combination of these indices as predictors of disease development or 72 
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mortality (10, 13). In the latest guidelines septal and lateral e’ peaks, average E/e’ ratio, LA volume 73 
index and peak tricuspid regurgitation velocity are recommended for use as indices for identification 74 
of diastolic dysfunction (10). However, no current population-based cohort has yet the power to 75 
examine the predictive value of these newest indices, but several including the Tromsø Study have the 76 
possibility to validate the older guidelines, but so far this has not been done. Redfield et al. validated a 77 
tissue Doppler, mitral and pulmonary vein flow derived definition of diastolic dysfunction against 78 
total mortality in a general population, but only tissue Doppler indices is still part of guideline defined 79 
diastolic dysfunction (14). The latest guideline have been validated against left ventricular end-80 
diastolic pressure with a high negative predictive value 93% and area under the curve (AUC) of 0.78 81 
(15), but only the individual components of the 2009 and 2016 guidelines have been validated against 82 
mortality and morbidity (16). 83 
Our aim was to study the long-term risk of all-cause mortality according to diastolic dysfunction 84 
measured as LA diameter and the mitral flow Doppler markers such as DT and E/A ratio using a 85 
population-based cohort. In addition, we tested the hypothesis that outcome derived cut-off values of 86 
diastolic dysfunction indices are more accurate for predicting fatal outcomes than normal cut-off 87 
values derived from a general population.  88 
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Methods 89 
Study population 90 
The Tromsø Study was initiated in 1974 as a prospective cohort study with the primary aim of 91 
assessing the role of modifiable risk factors for cardiovascular diseases. The study design has been 92 
described in detail previously (17). At present, seven consecutive surveys have been conducted. Both 93 
total birth cohorts and random samples from the general population of the Tromsø municipality were 94 
invited to participate, and many of the participants attended several surveys. Echocardiography was 95 
performed on a random selection of participants in the Tromsø 4 (1994-1995), Tromsø 5 (2001) and 96 
Tromsø 6 (2007-2008) surveys. 97 
A total of 3272 participants of the Tromsø 4 survey underwent echocardiographic examination. Of 98 
these, 1946 and 1462 had another echocardiographic examination in the Tromsø 5 and/or Tromsø 6 99 
surveys, respectively (Fig. 1). The reason that some participants at Tromsø 4 did not have further 100 
echocardiography examinations at Tromsø 5 and Tromsø 6 are various. They include moving away 101 
from the Tromsø municipality (n=155, out of them n=21 died afterwards), emigration from Norway 102 
(n=18), non-attendance despite being invited (n=368) and death (n=457) between Tromsø 4 and 103 
Tromsø 6 survey dates.  104 
For the purposes of this analysis we excluded those aged 50 years or younger (n=470), those with 105 
atrial fibrillation (n=39) during echocardiographic examination to prevent potential inaccuracy of DT 106 
measurements and those who had LVEF<50% (n=37) in the Tromsø 4 survey. Following these 107 
exclusions, 2734 participants were included in the analyses, each having had echocardiography at 108 
Tromsø 4 and possibly at later sweeps. The numbers included in analyses of specific endpoints were 109 
slightly smaller due to missing data on these parameters: 2616 participants for LA diameter analysis, 110 
2691 participants for DT analysis, and 2699 participants for E/A ratio analysis. We included 1875 111 
participants from the Tromsø 6 survey in additional analysis of the ratio of mitral peak velocity of 112 
early filling (E) to early diastolic mitral annular velocity (e’) (E/e’ ratio).  113 
Data collection 114 
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Information on risk factors and comorbidities was obtained from self-administered questionnaires. 115 
Participants provided information on their date of birth, sex, current smoking (yes/no), leisure time 116 
physical activity and current use of antihypertensive treatment (yes/no), history of angina (yes/no), 117 
myocardial infarction (yes/no), stroke (yes/no) (17). Body mass index was defined as weight 118 
(kg)/height (m2). Blood pressure was measured using an automated device Dinamap Pro care 300 119 
Monitor (GE Medical Systems Information Technologies, Tampa, FL, USA). Three readings were 120 
made after 2 minutes’ rest and separated by 1-minute intervals. The mean of the last two readings was 121 
used in the analysis. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic 122 
blood pressure ≥ 90 mm Hg or self-reported use of antihypertensive medication. Non-fasting serum 123 
levels of total cholesterol and glycated haemoglobin (HbA1c) were measured according to the 124 
previously described procedure (17, 18).  125 
Echocardiography imaging 126 
The echocardiography in the Tromsø 4 survey was performed by two expert cardiologists using a 127 
Vingmed CFM 750 ultrasound scanner (Vingmed Sound A/S, Horten, Norway), and details have been 128 
described previously (7). In the Tromsø 5 and 6 surveys, Acuson Seqoia C258 or C512 scanner 129 
(Acuson, Mountain view, California, USA) were used (19). Coefficients of variation for intra- and 130 
interobserver variability in the Tromsø 4-6 surveys were less than 10% for chamber dimensions and 131 
Doppler-derived values (19, 20). 132 
Echocardiographic assessment was performed with the use of standard imaging planes in the left 133 
lateral decubitus position according to ASE and EACVI  recommendations (12). All of the 134 
echocardiographic measurements were performed online once per examination, but remeasured online 135 
if deviating from eye-balled estimates. M-mode echocardiography was used for LA diameter 136 
measurement. LA was measured from the posterior aortic wall to the posterior LA wall using both the 137 
parasternal long-axis and short axis view perpendicular to the aortic root long axis at the level of the 138 
aortic sinuses by using the leading-edge to leading-edge convention. LA diameter measurement was 139 
performed during end ventricular systole. Body surface area indexed LA diameter (LA BSA) as 1.5-140 
2.3 cm/m2 was considered as normal cut-off value range both for men and women. BSA was 141 
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calculated by the Du Bois formula (BSA = [weight {kg} 0.425 × height {cm} 0.725] × 0.007184) 142 
(21). 143 
Doppler examination was performed using the apical 4-chamber view with placing of the 2-mm 144 
Doppler sample volume between the mitral leaflet tips. For Doppler measurements the insonation 145 
angle was kept as perpendicular as possible toward the mitral inflow to obtain maximal velocity flow 146 
in early diastole. Spectral gain was adjusted until the flow curve became clear relatively to the 147 
background (22). Normal values of DT were considered as 140-220 ms. E/A ratio between 0.8-1.5 148 
characterize a normal filling pattern (10). Values of E/e’ ratio used in analysis were within 4-25. 149 
Follow-up and outcome data   150 
Subjects included in the analysis contributed to risk from the date of attendance of the Tromsø 4 151 
survey until date of death, date of emigration from Norway or the end of follow-up on 31st December 152 
2016, whichever came first. Of the 2734 aged > 50 years who had echocardiography at the Tromsø 4 153 
survey, 1399 died during the follow-up period. Table I shows the numbers of participants and deaths 154 
according to which sweeps they were examined in. In the Cox model we treated the indices of 155 
diastolic dysfunction as time varying covariates. Those participants who had repeat echocardiography 156 
examinations in T5 or T6, were still free of atrial fibrillation, and had LVEF≥50%, had their indices of 157 
diastolic dysfunction and values for other covariates updated. E/e’ ratio was measured only in the 158 
Tromsø 6 survey, giving a follow-up of only 10 years for this parameter. 159 
The all-cause mortality endpoint was identified by linkage of the participants to the National Causes of 160 
Death Registry at the Norwegian Institute of Public Health using personal identification number. 161 
Information on the participants who had emigrated from Tromsø was obtained through the Population 162 
Register of Norway. 163 
Statistical methods 164 
Means with standard deviations and proportions were used to describe baseline characteristics of the 165 
study participants according to the three categories of LA diameter (<1.5 cm/m2; 1.5-2.3 cm/m2; >2.3 166 
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cm/m2), DT (<140 ms; 140-220 ms; >220 ms), and E/A ratio (<0.8; 0.8-1.5; >1.5). Means (except for 167 
age) and proportions were adjusted for age using linear or logistic regression, respectively. 168 
Associations of the three echocardiographic variables with all-cause mortality were assessed using 169 
time dependent Cox proportional hazards regression models with fractional polynomials of LA 170 
diameter, DT and E/A ratio as the main predictors. Baseline information for the participants can 171 
change during a follow-up period of 23 years. To take into account these changes we updated baseline 172 
information for those participants who also attended following surveys using time-dependent Cox 173 
regression. Models were tested for possible interactions between sex and LA diameter, DT, E/A ratio 174 
and E/e’ ratio. We found no interaction between sex and LA diameter, sex and DT, sex and E/A ratio, 175 
or sex and E/e’ ratio (p=0.489, p=0.696, p=0.199 and 0.730 respectively), and therefore results were 176 
presented for men and women combined. We chose the best-fitting fractional polynomials of LA 177 
diameter, DT, E/A ratio and E/e’ ratio while adjusting for sex and fractional polynomials of age using 178 
the Akaike information criterion (23). Hazard ratios (HRs) were estimated for a range of LA diameter 179 
values from 1.1 to 4.0 cm/m2, using 1.8 cm/m2 as the reference value, for a range of DT levels from 80 180 
to 300 ms with 155 ms as the reference value, for a range of E/A ratio levels from 0.3 to 4.0 with 1.1 181 
as the reference value and for a range of  E/e’ ratio from 4 to 25 with 4 as the reference value. HRs 182 
with 95% confidence intervals (CIs) were adjusted for sex and fractional polynomials of age because 183 
we expected non-linear associations between age and endpoint. In order to estimate the independent 184 
effect of left ventricular filling indices on all-cause mortality we adjusted the model for systolic blood 185 
pressure, total cholesterol, body mass index, smoking, antihypertensive treatment, history of stroke, 186 
angina and myocardial infarction. Likelihood ratio test between a model with and model without 187 
fractional polynomial terms of LA diameter, DT, E/A ratio or E/e’ ratio were used to test the 188 
associations. The proportional hazard assumption was met in all models. 189 
The best cut-off values for LA diameter, DT and E/A ratio were estimated using receiver operating 190 
characteristic (ROC) curves and AUCs. We used the maximum value of Youden’s index as a criterion 191 
for selecting the optimal cut-off points for LA diameter, DT and E/A ratio (24). For the two latter with 192 
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an U-shaped relation to risk, ROC curves were estimated for the upper and lower part of values 193 
separately. 194 
A two-sided p<0.05 was considered statistically significant. All statistical analyses were performed 195 
using SAS statistical package, version 9.4 (SAS Institute, Cary, NC). 196 
Ethical considerations 197 
The study conformed to the principles outlined in the Declaration of Helsinki, and the Tromsø Study 198 
protocol was approved by the Regional Committee for Medical and Health Research Ethics, North 199 
Norway (2009/2536/REK North). Informed consent was obtained from all individual participants 200 
included in the study.  201 
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Results 202 
Baseline characteristics 203 
The baseline clinical and echocardiographic characteristics of the study participants are presented 204 
according to the three ASE and EACVI categories of LA diameter (Table II), DT (Table III), and E/A 205 
ratio (Table IV).  206 
LA diameter, DT, E/A and E/e’ ratio’s and all-cause mortality  207 
We found that models with LA diameter, DT and E/A ratio adjusted for age and sex showed the very 208 
similar pattern of HRs compared to the fully adjusted models. We identified a U-shaped association 209 
between LA diameter and all-cause death (Fig. 2). When adjusted for sex and age, participants with 210 
LA diameter of 1.1 cm/m2 had a higher risk of death compared with those with LA diameter of 1.8 211 
cm/m2 (HR=4.35; 95% CI 1.84 to 10.30). For values above the reference significant increase in the 212 
risk of death was observed starting from 2.1 cm/m2 (HR=1.09; 95% CI 1.01 to 1.18). In the fully 213 
adjusted model, risk of death was 4.60 and 5.72 times higher for those with LA diameter of 1.1 cm/m2 214 
and 4.0 cm/m2, respectively when compared to LA diameter of 1.8 cm/m2. 215 
LA diameter of 1.8 cm/m2 corresponded to the lowest HR in both age- and sex-adjusted and fully 216 
adjusted models (Fig. 2) and accordingly we estimated the optimal cut-off points based on ROC curve 217 
analysis above and below this value. The AUC for LA diameter values ≤ 1.8 cm/m2 was 0.56 218 
(p=0.117). The optimal lower cut-off value for LA diameter was estimated as 1.7 cm/m2. For those 219 
with LA diameter > 1.8 cm/m2 the AUC value was 0.60 (p<0.001) with an optimal upper cut-off point 220 
for LA diameter of 2.3 cm/m2 (Table V). 221 
 222 
Association between mitral peak E DT and risk of all-cause death was U-shaped (Fig. 3). In the sex- 223 
and age-adjusted model, those with DT of 80 ms had approximately four times higher risk of death 224 
compared with the reference value of 155 ms (HR=4.65; 95% CI 2.37 to 9.12). Those with DT of 300 225 
ms had a 55% increased risk of death compared with the reference value. In the fully adjusted model, 226 
when compared to the reference DT of 155 ms, HRs for DT of 80 ms and DT of 300 ms were 5.37 227 
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(95% CI 2.64 to 10.94) and 1.44 (95% CI 1.23 to 1.68), respectively. DT less than the reference of 155 228 
ms was associated with increased risk of death starting from DT of 130 ms (HR=1.09; 95% CI 1.02 to 229 
1.17) (Fig. 3).  230 
The DT value of 155 ms conferred the lowest risk and the population was accordingly divided at this 231 
value. For those with DT levels ≤155 ms (AUC=0.56, p=0,030) an optimal cut-off point was 150 ms. 232 
AUC for those with DT >155 ms was 0.60, p<0.001. Here a value of 200 ms was the best cut-off point 233 
with 67% sensitivity and 50% specificity (Table V).  234 
Similarly to LA and DT, the association between mitral valve E/A ratio and risk of death was U-235 
shaped. Sex- and age-adjusted HRs of death for E/A ratio of 0.3 and for E/A ratio of 4.0 compared 236 
with E/A ratio of 1.1 was 4.63 and 5.00, respectively. In the fully adjusted model HRs for E/A ratio of 237 
0.3 and of 4.0 in comparison with the reference value were 4.12 (95% CI 2.66 to 6.40) and 4.50 (95% 238 
CI 2.64 to 7.67), respectively (Fig. 4). 239 
Results of the analysis of E/A ratio’s and HR’s showed that a value of 1.1 had the lowest HR and at 240 
this value the population was divided in two groups. Lower part of values with E/A ratio ≤ 1.1 had an 241 
AUC of 0.54, p<0.001. An optimal cut-off was considered as 0.6. Results of ROC curve analysis for 242 
those with E/A ratio > 1.1 showed that AUC was 0.58, p<0.001. The best cut-off value for E/A ratio 243 
>1.1 equals 1.2 with levels of sensitivity of 67% and specificity of 46% (Table V).  244 
 245 
Optimal cut-off values for all-cause mortality derived from time-dependent Cox regression models 246 
adjusted for age and sex were 1.4-2.1 cm/m2 for LA diameter, 120-185 ms for DT and 0.8-1.4 for E/A 247 
ratio (Table V). 248 
 249 
Comparison between ROC curves and AUC’s of models with new outcome derived, maximal Youden 250 
index based reference values with different variables showed that the largest AUC of 0.63 was 251 
estimated when LA diameter cut-off was combined with similarly derived cut-offs for DT and E/A 252 
ratio. Combination of LA diameter with DT gave similar AUC. Other combinations of LA diameter 253 
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with left ventricular filling indices did not result in increase of AUC. HR derived cutoffs produced 254 
identical AUC’s and were not presented.  255 
ROC analysis using ASE and EACVI recommended cut-offs revealed the highest AUCs when LA 256 
diameter was combined with DT and with DT+E/A ratio. These combinations gave AUCs of 0.63. 257 
 258 
We revealed a cubic association between E/e’ ratio and all-cause mortality (Fig. 5). In the age- and 259 
sex-adjusted model those with E/e’ of 25 had 3.48-fold increase of overall mortality risk in 260 
comparison with reference value of 4. In the fully-adjusted model the risk of all-cause mortality in 261 
those with the extreme E/e’ value compared with E/e’ of 4 was 4.54 (95% CI 1.80 to 11.44).  262 
The AUC for models with E/e’ ratio, LA diameter, DT, or E/A ratio as predictor of all-cause mortality 263 
from 2007 and onwards were 0.59 (95% CI 0.54-0.63), 0.60 (95% CI 0.55-0.64), 0.62 (95% CI 0.58-264 
0.66), 0.60 (95% CI 0.56-0.64) respectively. No significant difference was found between the models 265 
with echocardiographic determinants of diastolic dysfunction and all-cause mortality.   266 
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Discussion 267 
Results overview 268 
Our study reveals that echocardiographic markers of diastolic dysfunction such as LA diameter, DT 269 
and E/A ratio can be used for prediction of all-cause mortality risk. We were able to estimate HRs for 270 
all of the described parameters, assess new outcome derived cut-off points for them and describe the 271 
best combinations of echocardiographic markers for all-cause mortality outcome prediction. The 272 
association remained U-shaped after additional adjustment for systolic blood pressure, body mass 273 
index, total cholesterol, smoking, antihypertensive treatment, history of stroke, angina and myocardial 274 
infarction. It shows that LA diameter, DT and E/A ratio each have independent effects on all-cause 275 
mortality also after adjustment for sex, age and cardiovascular risk factors. We also used all-cause 276 
mortality risk estimation models for assessing optimal cut-offs of the left ventricular filling indices. 277 
These cut-offs were slightly different from those obtained with maximal Youden index but gave 278 
identical prediction ability for all-cause mortality outcome. 279 
Comparison with other studies 280 
Left atrial diameter 281 
LA diameter has been shown to be an important prognostic parameter of mortality in several but not 282 
all studies conducted in general population samples (5, 25). Pritchett et al. reported that BSA-indexed 283 
LA volume was not associated with all-cause mortality when adjusted for age, gender, ejection 284 
fraction and diastolic dysfunction grade (26). Diversity in results may be explained by differences in 285 
the study populations, methods of LA diameter measurement and indexation. 286 
In our study, the HRs for LA diameter above the reference of 1.8 cm/m2 increased from 1.12 (1.01-287 
1.23) to 5.72 (3.65-8.95) in the fully adjusted model corresponding to previous publications (25). The 288 
underlying mechanisms linking an enlarged LA diameter with increased all-cause mortality have been 289 
described previously (27). Elevated LA filling pressures, decreased flow velocities in LA appendages, 290 
atrial fibrillation as well as structural heart disease and hypertension are among those mechanisms 291 
which result in all-cause mortality risk increase.  292 
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A novel finding of our study is that LA diameter below 1.5 cm/m2 independently increases risk of all-293 
cause death. This finding is supported by a few recent studies, however with several limitations. 294 
Aviram et al. found that decreased LA volume was associated with increased mortality risk in patients 295 
with acute pulmonary embolism (28). Rozenbaum et al. also reported that patients with very small LA 296 
volume index <24 ml/m2 had HR of 3.6 (95% CI: 1.46-8.87) for all-cause mortality (29). Limitations 297 
of these studies were small sample sizes and short follow-up periods. Acquisition of images in these 298 
studies were based on computed tomography. To our knowledge, there is no literature data on the 299 
association of small atrial diameters and all-cause mortality rates based on two-dimensional 300 
echocardiography.  301 
One of the possible explanation of association between small LA size and mortality could be a 302 
decrease of LA emptying fraction, a functional parameter, which is independently associated with LA 303 
remodeling and mortality prediction (30). 304 
According to our findings 11 individuals with LA diameter <1.5 cm/m2 died during the follow-up. 305 
Cause of death of two individuals was not established. Only one person had myocardial infarction as 306 
cause of death indicating a maximal possible proportion of cardiovascular death to 30%. In patients 307 
with LA diameter >2.3 cm/m2, most of the mortality were due to myocardial infarction 191 (40.1%) 308 
and ischemic heart disease 78 (16.4%). Other causes of death in this group were; stroke 48 (10.1%), 309 
sudden death 10 (2.1%) and subarachnoid haemorrhage 1 (0.2%) indicating less than half the risk of 310 
CVD death for small atria compared to enlarged.  311 
We defined lower and upper cut-offs with optimal sensitivity and specificity levels using the Youden 312 
index. Thus, lower reference cut-off value for LA diameter was 1.7 cm/m2 (ROC curve p-313 
value=0.117) which is higher than the ASE and EACVI recommended value of 1.5 cm/m2. According 314 
to our findings the value of 1.5 cm/m2 has a higher sensitivity level of 81% which corresponds to the 315 
higher negative predictive value. The upper cut-off point was 2.3 cm/m2 with a 46% sensitivity and 316 
71% specificity and had significantly higher risk than 2.1 cm/m2, which conforms to recent 317 
recommendations (12). 318 
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Mitral peak E deceleration time 319 
In our study the optimal cut-off level for lower DT reference value was defined as 150 ms which is 320 
higher than the current normality-based cut-off of 140 ms (10). It was a key parameter in Redfield 321 
definition (14) and has shown strong independent predictive ability in patient population with 322 
myocardial infarction (31). Our results demonstrate that risk of all-cause mortality increased gradually 323 
with decreasing DT starting from 130 ms when compared with the reference value of 155 ms in the 324 
fully adjusted model. Our findings can be explained by the inverse relation of DT to the left ventricle 325 
filling pressure and association of a short DT with restrictive filling pattern, which increases the risk of 326 
left ventricular dilatation. 327 
We found an optimal upper cut-off value of 200 ms with 67% sensitivity and 50% specificity for 328 
identification of a fatal outcome. Prolonged DT is associated with low left ventricular filling pressures 329 
and impaired ventricular relaxation, which lead to progression of diastolic dysfunction and heart 330 
failure. Although the prognostic value of elevated DT has been documented before (32), this is the 331 
first estimation of the diagnostic accuracy of different DT values for prediction of all-cause mortality 332 
in a general population. 333 
Unlike the U-shaped relationships between all-cause mortality and LA size or E/A ratio with a narrow 334 
normal range, DT effect is linked to extreme values at each end of a wide normal range in 335 
concordance with ASE and EACVI normality cut-offs. However, our approach of using outcome-336 
derived values allowed narrowing the fraction of DT middle values and improves risk assessment non-337 
significantly.    338 
E/A ratio 339 
Results from the second wave in the Strong Heart Study indicated that in middle-aged and elderly 340 
participants, an E/A ratio level above 1.5 was independently associated with a 2-fold increase in all-341 
cause mortality risk (33). E/A levels below 0.6 were similarly associated with increased mortality risk. 342 
In our study the risk of all-cause mortality increased gradually for E/A values above 1.3. Risk of all-343 
cause mortality increased also with decreasing E/A ratios starting from 0.8.  344 
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Analysis of the predictive ability of E/A ratio showed that optimal cut-offs differed from those 345 
recommended by ASE and EACVI. Thus, the lower optimal cut-off was found as 0.6 with a 346 
corresponding 17% sensitivity and 89% specificity. Upper cut-off value of 1.2 had a specificity level 347 
of 46% which is lower than ASE and EACVI guideline based E/A ratio value of 1.5 (specificity 59%) 348 
with all-cause mortality as outcome.  349 
E/e’ ratio 350 
Our findings suggest that an elevated E/e’ ratio is independently associated with increased risk of all-351 
cause mortality in a general population. This is in contrast to Mogelvang et al. in the Copenhagen City 352 
Heart Study who found no association of E/e’ with overall mortality (34). Kuznetsova et al. reported 353 
borderline association of E/e’ratio and risk of cardiac events (16). These studies had 90 and 59 cases 354 
respectively and half the follow up time of our study where 240 cases and 10 years follow up increases 355 
power in support of our finding. Interestingly E/e’ did not have a superior predictive ability for overall 356 
mortality when compared with other diastolic dysfunction markers.  357 
Comparison of prognostic values of LA diameter, DT and E/A  358 
We aimed to explore the hypothesis that reference values based on outcome data would predict all-359 
cause mortality better than those recommended by ASE and EACVI. The outcome-derived model, 360 
which combines LA diameter, DT and E/A ratio showed the best prediction on all-cause mortality, but 361 
not significantly different from the model with only LA diameter and DT included.  362 
Using the cut-off values from current ASE and EACVI classification of diastolic dysfunction gave the 363 
same AUCs for LA diameter as Youden index based outcome derived cut-offs. For models with the 364 
three variables combined the largest AUC was detected in LA diameter+DT+E/A ratio model 365 
(AUC=0.63, p<0.001) which was the same as in a model with ASE and EACVI cut-off values. When 366 
assessing the incremental value of each parameter both DT and E/A ratio added prognostic value to 367 
LA diameter, but E/A ratio did not add to the prognostic accuracy of LA diameter in combination with 368 
DT.  369 
Study strengths and limitations 370 
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This was a large prospective population-based study with a long follow-up period. The prospective 371 
design of the Tromsø study and a random sample of a large age span from the general population with 372 
a high attendance rate increases generalizability to other Caucasian populations. Another strength was 373 
the updating of baseline values as the participants attended following surveys. Although biplane or 3D 374 
echocardiography are now regarded as the most accurate methods of LA volume estimation, M-mode 375 
anteroposterior LA diameter has higher intra- and interobserver reproducibility especially while 376 
assessing minimal atrial dimensions (35).   377 
A main limitation of the study is that we used M-mode based linear measurements of LA which is less 378 
accurate than those based on LA volumes performed by biplane method. Unfortunately, LA 379 
echocardiographic data from the Tromsø 4-6 surveys contain only M-mode measurements. Our 380 
findings need validation using LA volumes which will be explored in future studies. The raw images 381 
from Tromsø 4-6 surveys are available as well as measurements of volumes from the latest Tromsø 7 382 
survey (2015-2016) which when enough endpoints have occurred, will give us the possibility to 383 
perform further analysis of LA volumes and diastolic dysfunction patterns according to the recent 384 
recommendations. Tricuspid regurgitation was not measured in the Tromsø 4-6 surveys. E/A ratio 385 
pseudonormal filling pattern was not considered in our study. However, individuals with severe left 386 
ventricular dysfunction were excluded from the study, and we suppose that influence of 387 
pseudonormalisation was relatively small. Information on smoking, current use of antihypertensive 388 
treatment, and history of angina, myocardial infarction and stroke was self-reported. It could 389 
potentially result in the presence of information bias. Models were not adjusted for laboratory markers 390 
such as N-terminal pro brain natriuretic peptide due to inconsistent presence of these parameters in all 391 
studied waves of the Tromsø Study. The maximal Youden index as classic data-driven approach for 392 
optimal cut-off estimation has its own disadvantages. The main is that Youden index is not sensitive 393 
for differences in the sensitivity and specificity of the test. To avoid the limitation we presented 394 
optimal cut-off points based on HR’s along with cut-off values based on maximal Youdex index. The 395 
study only assesses the ability to predict mortality. As presence of diastolic dysfunction is associated 396 
with an increased risk of developing heart failure as well as death, estimation of cut-off values based 397 
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on a composite endpoint of death and heart failure could have yielded different results and potentially 398 
a higher predictive accuracy. 399 
Conclusions 400 
Our study concludes that not only enlarged but also small LA diameter is associated with increased 401 
all-cause mortality risk. Using our new outcome derived cut-offs of LA diameter, DT and E/A ratio 402 
did not result in a better predictive ability for all-cause mortality in comparison with current ASE and 403 
EACVI recommended cut-off points. A combination of the Doppler based LV filling parameter DT 404 
with LA diameter is preferable while assessing risk of all-cause mortality, while E/A ratio did not add 405 
incremental value.  406 
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 1 
Tables 
 
Table I Numbers of participants and deaths included in analyses according to the sweeps of the 
Tromsø Study in which they had echocardiographic examinations 
 Number of participants Number of deaths 
Tromsø 4 only 914 710 
Tromsø 4 + Tromsø 5 694 459 
Tromsø 5 + Tromsø 6 252 61 
Tromsø 4 + Tromsø 5 + Tromsø 6 874 169 
Total 2734 1399 
 
 2 
Table II Baseline characteristics of study participants by left atrial diameter (n=2616); the Tromsø 
Study 1994-1995 
Characteristics Left atrial diameter, cm/m2 P value 
 < 1.5 
(n=24) 
1.5 – 2.3  
(n=1685) 
> 2.3 
(n=907) 
 
Death 11 (45.8) 780 (46.3) 524 (57.8) <0.001 
Sex (M-male, F-female) M-12 (50.0) 
F-12 (50.0) 
M-895 (53.1) 
F-790 (46.9) 
M-392 (43.2) 
F-515 (56.8) 
<0.001 
Age, years 62.3 (7.1) 62.2 (6.1) 64.7 (6.3) <0.001 
BMI, kg/m2 25.5 (3.4) 26.2 (3.9) 26.1 (4.0) 0.630 
DBP, mm Hg 85.4 (9.6) 84.2 (12.1) 84.5 (13.1) 0.428 
SBP, mm Hg 148.7 (21.0) 145.9 (21.4) 149.4 (23.0) <0.001 
Total cholesterol, mmol/L 6.40 (1.12) 6.84 (1.25) 6.81 (1.19) 0.215 
HbA1c, % 5.27 (0.36) 5.49 (0.68) 5.49 (0.81) 0.199 
History of stroke 1 (3.7) 34 (1.9) 30 (2.5) 0.486 
History of angina 2 (7.7) 125 (7.1) 133 (11.8) <0.001 
History of myocardial 
infarction 
0 (0.0) 91 (5.4) 79 (7.6) 0.076 
Smoking  9 (36.7) 551 (31.9) 250 (28.6) 0.195 
Physical activity    0.742 
   Low 3 (13.8) 196 (11.9) 122 (12.3)  
 3 
   Moderate 5 (21.9) 645 (38.1) 336 (38.8)  
   Active 13 (59.4) 749 (45.3) 394 (43.5)  
   Highly active 1 (4.4) 73 (4.3) 42 (4.9)  
Antihypertensive treatment 4 (16.4) 173 (10.2) 200 (19.7) <0.001 
DT, ms  226.6 (64.5) 204.6 (43.2) 201.1 (46.7) 0.067 
E/A ratio 0.85 (0.23) 0.96 (0.27) 1.02 (0.36) 0.086 
 
Values in the table are mean (standard deviation) or number (%). Means (except for age) and 
proportions were adjusted for age using linear or logistic regression, respectively 
BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure, HbA1c glycated 
haemoglobin, DT mitral peak E deceleration time, E/A mitral peak E to peak A ratio, LA left atrium  
  
 4 
Table III Baseline characteristics of study participants by deceleration time (n=2691); the Tromsø 
Study 1994-1995 
Characteristics Deceleration time, ms P value 
 < 140  
(n=71) 
140 - 220 
(n=1912) 
> 220 
(n=708) 
 
Death 39 (54.9) 863 (45.1) 464 (65.5) <0.001 
Sex (M-male, F-female) M-27 (38.0) 
W-44 (62.0) 
M-902 (47.2) 
W-1010 (52.8) 
M-404 (57.0) 
W-304 (43.0) 
<0.001 
Age, years 62.8 (6.6) 62.4 (6.1) 65.1 (6.2) <0.001 
BMI, kg/m2 26.7 (3.4) 26.1 (4.0) 26.3 (3.9) 0.307 
DBP, mm Hg 86.2 (13.5) 83.7 (12.1) 86.0 (13.1) <0.001 
SBP, mm Hg 151.7 (23.0) 146.8 (21.7) 148.2 (22.9) <0.001 
Total cholesterol, mmol/L 7.00 (1.36) 6.88 (1.23) 6.68 (1.23) 0.006 
HbA1c, % 5.52 (0.60) 5.48 (0.69) 5.52 (0.84) 0.073 
History of stroke 2 (2.5) 41 (2.0) 26 (2.7) 0.441 
History of angina 10 (12.5) 198 (9.6) 65 (6.7) 0.024 
History of myocardial 
infarction 
11 (14.8) 117 (6.0) 48 (5.6) 0.010 
Smoking  17 (23.5) 588 (30.0) 243 (36.1) 0.006 
Physical activity    0.225 
   Low 13 (18.0) 217 (11.5) 102 (13.3)  
 5 
   Moderate 28 (39.3) 754 (39.5) 232 (34.7)  
   Active 28 (39.5) 834 (44.2) 325 (46.7)  
   Highly active 2 (2.8) 85 (4.4) 32 (4.8)  
Antihypertensive treatment 19 (26.5) 254 (13.0) 124 (14.6) 0.006 
LA diameter, cm/m2 2.29 (0.30) 2.21 (0.32) 2.17 (0.33) 0.070 
E/A ratio 1.16 (0.49) 1.01 (0.29) 0.87 (0.24) <0.001 
 
Values in the table are mean (standard deviation) or number (%). Means (except for age) and 
proportions were adjusted for age using linear or logistic regression, respectively 
BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure, HbA1c glycated 
haemoglobin, DT mitral peak E deceleration time, E/A mitral peak E to peak A ratio, LA left atrium  
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Table IV Baseline characteristics of study participants by mitral peak E to peak A ratio (n=2699); the 
Tromsø Study 1994-1995 
Characteristics E/A ratio P value 
 < 0.8 
(n=786) 
0.8 – 1.5 
(n=1800) 
> 1.5 
(n=113) 
 
Death 510 (64.9) 811 (45.1) 50 (44.3) <0.001 
Sex (M-male, F-female) M-367 (46.7) 
W-419 (53.3) 
M-899 (49.9) 
W-901 (50.1) 
M-68 (60.2) 
W-45 (39.8) 
0.021 
Age, years 65.9 (6.0) 62.1 (6.0) 62 (6.3) <0.001 
BMI, kg/m2 26.8 (4.1) 25.9 (3.9) 24.9 (3.6) <0.001 
DBP, mm Hg 88.3 (13.3) 82.9 (11.8) 80.2 (11.5) <0.001 
SBP, mm Hg 152.3 (22.9) 145.4 (21.0) 143.1 (21.4) <0.001 
Total cholesterol, mmol/L 6.86 (1.25) 6.83 (1.23) 6.59 (1.13) 0.039 
HbA1c, % 5.54 (0.87) 5.47 (0.67) 5.39 (0.50) <0.001 
History of stroke 31 (2.8) 35 (1.9) 3 (3.0) 0.209 
History of angina 94 (8.4) 157(8.3) 19 (19.1) 0.002 
History of myocardial 
infarction 
63 (6.3) 94 (5.2) 18 (18.0) <0.001 
Smoking  238 (32.5) 581(31.3) 31 (25.1) 0.288 
Physical activity    0.242 
   Low 122 (13.9) 208 (11.9) 7 (6.8)  
 7 
   Moderate 280 (37.9) 687 (38.1) 46 (39.2)  
   Active 348 (44.3) 790 (44.7) 53 (47.9)  
   Highly active 24 (3.2) 89 (4.9) 6 (5.1)  
Blood pressure treatment 153 (15.9) 228 (12.7) 16 (15.8) 0.077 
DT, ms 221.5 (52.1) 197.8 (38.6) 179.3 (35.5) <0.001 
LA diameter, cm/m2 2.16 (0.32) 2.21 (0.31) 2.36 (0.41) <0.001 
 
Values in the table are mean (standard deviation) or number (%). Means (except for age) and 
proportions were adjusted for age using linear or logistic regression, respectively 
BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure, HbA1c glycated 
haemoglobin, DT mitral peak E deceleration time, E/A mitral peak E to peak A ratio, LA left atrium  
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Table V Optimal cut-off values of left ventricular filling indices associated with all-cause mortality 
outcome; the Tromsø Study 
  Optimal 
cut-off 
valuesa 
Sensitivity/
Specificity, 
% 
Youden 
index 
AUC* (95% CI) ROC 
curve p-
value 
Optimal 
cut-off 
valuesb  
LA diameter, 
cm/m2 
Upper 
cut-off 
2.3 46/71 0.17 0.60 (0.58-0.62) <0.001 2.1 
 Lower 
cut-off 
1.7 71/46 0.16 0.56 (0.49-0.63) 0.117 1.4 
DT, ms Upper 
cut-off 
200 67/50 0.17 0.60 (0.58-0.63) <0.001 185 
 Lower 
cut-off 
150 98/18 0.16 0.56 (0.51-0.62) 0.030 120 
E/A ratio Upper 
cut-off 
1.2 67/46 0.14 0.58 (0.53-0.63) <0.001 1.4 
 Lower 
cut-off 
0.6 17/89 0.06 0.54 (0.52-0.57) <0.001 0.8 
 
aOptimal cut-off values for all-cause mortality outcome estimated according to the highest Youden 
index 
bOptimal cut-off values for all-cause mortality outcome derived from time-dependent Cox regression 
models adjusted for age and sex 
*AUCs for ranges which include optimal (maximal Youden index based) upper and lower cut-off 
values. Ranges are estimated above and below the values with lowest HRs for LA diameter: 1.8 
cm/m2; for DT: 155 ms; for E/A ratio: 1.1 
 9 
LA left atrium, DT mitral peak E deceleration time, E/A mitral peak E to peak A ratio, AUC area under 
the curve, ROC receiver operating characteristic 
 
Figure legends 
Fig. 1 Flowchart of the participants with performed echocardiographic examination. The Tromsø 
Study 
aNumbers in boxes represent numbers of subjects examined with echocardiography in each wave of 
the Tromsø Study  
 
Fig. 2 Left atrial (LA) diameter and all-cause mortality. The Tromsø Study 
p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms 
of LA diameter 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, 
total cholesterol, stroke, angina, myocardial infarction, smoking, antihypertensive treatment  
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval 
 
Fig. 3 Mitral peak E deceleration time (DT) and all-cause mortality. The Tromsø Study 
p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms 
of DT 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, 
total cholesterol, stroke, angina, myocardial infarction, smoking, antihypertensive treatment  
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval 
 
Fig. 4 Mitral peak E to peak A ratio and all-cause mortality. The Tromsø Study 
p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms 
of E/A ratio 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, 
total cholesterol, stroke, angina, myocardial infarction, smoking, antihypertensive treatment 
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval 
 
Fig. 5 Mitral peak E to peak e’ ratio and all-cause mortality. The Tromsø Study  
p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms 
of E/e’ ratio 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, 
total cholesterol, stroke, angina, myocardial infarction, smoking, antihypertensive treatment 
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval 
 
 
 
 Fig. 1 Flowchart of the participants with performed echocardiographic examination. The Tromsø Study 
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Fig. 2 Left atrial (LA) diameter and all-cause mortality. The Tromsø Study 
 
p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms of LA diameter 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, total cholesterol, stroke, angina, myocardial infarction, smoking, 
antihypertensive treatment  
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval 
  
Fig. 3 Mitral peak E deceleration time (DT) and all-cause mortality. The Tromsø Study 
 
p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms of DT 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, total cholesterol, stroke, angina, myocardial infarction, smoking, 
antihypertensive treatment  
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval 
  
Fig. 4 Mitral peak E to peak A ratio and all-cause mortality. The Tromsø Study 
 
p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms of E/A ratio 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, total cholesterol, stroke, angina, myocardial infarction, smoking, 
antihypertensive treatment 
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval
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p-value: Likelihood ratio test between a model with and a model without fractional polynomial terms of E/e’ ratio 
*Adjusted for sex and fractional polynomials of age 
**Adjusted for sex, fractional polynomials of age, mean systolic blood pressure, body mass index, total cholesterol, stroke, angina, myocardial infarction, smoking, 
antihypertensive treatment 
HR hazard ratio, LCI lower 95% confidence interval, UCI upper 95% confidence interval
  
